UNSPSC 51341602: Tromantadine

This classification denotes an antiviral agent with the molecular formula C16H28N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier H191JFG8WA, chemically known as 2-(2-(dimethylamino)ethoxy)-n-tricyclo(3.3.1.13,7)dec-1-ylacetamide but generally known as tromantadine, which bears US NIH Compound Identifier 64377. European Medicines Agency schedules Tromantadine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11335MIG.

UNSPSC 51341602 Tromantadine is a Commodity code that nominally addresses a specific antiviral pharmaceutical product, but recent state and local procurement activity under this code shows little direct relevance to tromantadine itself. The most recent opportunities tagged to this code involve naloxone and drug deactivation systems, direct-to-manufacturer pharmacy programs, medical and first aid supplies for emergency response, and generic multi-source pharmaceuticals and OTC products — none of which are tromantadine or closely related antivirals. State and local issuing bodies pursuing activity under this code span county health departments (Seminole County, Florida), state health agencies (Texas Health and Human Services Commission), municipal fire and rescue divisions (City of Tampa), and cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance). The procurement approaches range from competitive sealed bidding for consumable medical supplies to RFIs for direct-to-manufacturer contracting models and formal RFPs for multi-state pharmaceutical distribution frameworks.

Geographic activity centers on Florida, Texas, and Minnesota, with multi-state reach through cooperative purchasing vehicles. Representative recent opportunities include Seminole County's IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually (due July 26, 2023), the City of Tampa's competitive bid for 169 line items of medical and first aid supplies for the Fire Department Rescue Division with an estimated contract value of $700,000.00 (due March 13, 2026), the Texas Health and Human Services Commission's RFI regarding therapeutic pharmacy initiative direct-to-manufacturer prescription programs (due April 3, 2026), and the Minnesota Multistate Cooperative Purchasing Alliance's RFP for generic multi-source pharmaceuticals and OTC products through authorized wholesalers (proposals due March 26, 2026). The code shows active procurement momentum but predominantly in pharmaceutical distribution, emergency medical supplies, and health benefit administration rather than in tromantadine-specific antiviral procurement.